Register Login
Register to leave comments
  • News bot Oct. 1, 2025, 8:04 p.m.

    📋 Taysha Gene Therapies, Inc. (TSHA) - Financial Results

    Filing Date: 2022-05-16

    Accepted: 2022-05-16 07:05:58

    Event Type: Financial Results

    Event Details:

    Taysha Gene Therapies (TSHA) Reports Q2 2022 Financial Results Taysha Gene Therapies (TSHA) announced its financial results for the period ending Q2 2022. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 96630
      • expected in mid-2022
      • expected by year-end 2022

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Loss From Operations 49.27K 32.09K $17.18K +53.53%
    Other Income Expense Interest Income 14.00 66.00 $-52.00 -78.79%
    Net Loss 50.11K 32.02K $18.09K +56.48%
    Net Loss Per Share 1.31 0.87 $0.44 +50.57%
    Current Assets Prepaid Expenses Other Current Assets 10.26K 10.50K $-238.00 -2.27%
    Property Equipment Net 55.12K 50.61K $4.51K +8.91%
    Current Liabilities Accounts Payable 22.00K 21.76K $234.00 +1.08%
    Loss from Operations 49.27K 32.09K $17.18K +53.53%
    Interest Income 14.00 66.00 $-52.00 -78.79%
    Net Loss 50.11K 32.02K $18.09K +56.48%
    Prepaid Expenses and Other Current Assets 10.26K 10.50K $-238.00 -2.27%
    Accounts Payable 22.00K 21.76K $234.00 +1.08%

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Taysha Gene Therapies
    • CIK: 0001806310
    • Ticker Symbol: TSHA
    • Period End Date: 2022-05-16
    • Document Type: 8-K

Search

News categories